DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Cervical Endometrioid Adenocarcinoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCervical Endometrioid Adenocarcinoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cervical endometrioid adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
A retrospective review of 23 patients treated with radiation for invasive cervical cancer who later developed endometrial carcinoma found a mean age at diagnosis of 64.4 years and an average latency of 14 years. Only 22% of these post-radiation endometrial cancers were stage I; 74% were grade 3. Histological subtypes included carcinosarcoma (35%), papillary serous (26%), and endometrioid (17%). Median survival was 24 months, with 2-year survival of 50% and 5-year survival of 21%. The authors concluded that endometrial cancers arising after pelvic radiation are predominantly high-risk subtypes and carry a poor prognosis.
A 2011 case report described a single patient diagnosed with type I endometrioid adenocarcinoma 19 years after definitive chemoradiation for cervical cancer. The authors noted that post-radiation uterine cancers are typically high stage, high grade, and type II histology, making this endometrioid case an exception.
A 2023 study used morphology, immunohistochemistry, and next-generation sequencing to analyse a single case of endometrioid adenocarcinoma with a "burrowing" pattern of cervical invasion. The cervical and endometrial tumours were found to be separate primaries, supporting a 2010 argument that such cases may represent two independent cancers rather than spread from one site. The authors stated that data on this phenomenon remain scarce.
No drug treatment is mentioned in any of these abstracts. What is missing is prospective data on how to distinguish synchronous primary endometrioid adenocarcinomas of the cervix and endometrium from metastatic disease, and whether that distinction changes management or outcomes. No trial has tested a specific therapy for post-radiation endometrial cancer, and no patient stratification strategy exists for this rare population.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 2003 · 47 citations
Development of endometrial cancer after radiation treatment for cervical carcinoma
AbstractOBJECTIVE: To detail the Memorial Sloan-Kettering Cancer Center and MD Anderson Cancer Center experience with 23 patients treated with radiation therapy for invasive cervical carcinoma who subsequently developed endometrial carcinoma. METHODS: We conducted a retrospective chart and pathology review on patients diagnosed with endometrial cancer between 1976 and 2000 who had previously received definitive radiation treatment for cervical cancer. Abstracted data included patient demographics, type of radiation therapy, histological grade, histological subtype, and stage of endometrial cancer. RESULTS: The mean age at endometrial cancer diagnosis was 64.4 years (range 53-80), and the average latency period from initial therapy to development of endometrial carcinoma was 14 years (range 6-27). Distribution by stage, grade, and histology was as follows: stage I, five (22%); stage II, one (4%); stage III, nine (39%); stage IV, seven (30%); unknown stage, one (4%); grade 1, one (4%); grade 2, three (13%); grade 3, 17 (74%); unknown grade, two (9%); carcinosarcoma, eight (35%); endometrioid, four (17%); papillary serous, six (26%); clear cell, one (4%); mucinous, one (4%); undifferentiated, one (4%); and unknown histology, two (9%). The median survival was 24 months, and the 2- and 5-year survival rates were 50% (95% confidence interval [CI] 31.4%, 78.9%) and 21% (95% CI 8.1%, 56.3%), respectively. CONCLUSION: Patients treated with definitive radiation therapy for invasive cervical cancer may still have viable endometrium at risk for neoplasia. Endometrial cancers that develop after radiation treatment have a preponderance of high-risk histological subtypes and, consequently, a poor prognosis.
Open Journal of Obstetrics and Gynecology · 2011 · 1 citations · open access
Type I endometrial cancer after chemoradiation therapy for carcinoma of the cervix: a case report
AbstractStandard treatment for cervical cancer has been radiation and chemotherapy. Ionizing radiation has been associated with damage to normal tissues included in the radiation field. Post-radiation uterine cancers are characterized by high stage, high grade, and a preponderance of type II histologic subtypes. We report a case of type I endometrioid adenocarcinoma diagnosed 19 years after definitive chemoradiation for cervical cancer.
International Journal of Gynecological Pathology · 2023 · 1 citations
Endometrioid Adenocarcinoma With “Burrowing” Invasion of the Cervix Represents a Separate Primary From the Concurrent Uterine Corpus Endometrial Endometrioid Adenocarcinoma: Histology, Immunohistochemistry, and Next-generation Sequencing Study of a Single Case
AbstractA small subset of endometrial endometrioid adenocarcinoma cases first reported in 2003, showed a distinct cervical component with a so-called "burrowing" invasion pattern. Initially, the cervical component was regarded as cervical involvement by the endometrial adenocarcinoma. However, a 2010 study argued that these cases actually might represent separate primary endometrial and cervical endometrioid adenocarcinomas. However, additional data on this topic are scarce. Here, we report a case of endometrioid adenocarcinoma with a "burrowing" cervical invasion that is morphologically distinct from the patient's endometrial endometrioid adenocarcinoma. By comparing the morphology, immunophenotype, and genetic profile obtained by next-generation sequencing, we demonstrated that the cervical and endometrial tumors were of 2 separate primaries. Our report adds additional data to this unique phenomenon, and will hopefully help to reignite interest in investigating this controversial topic.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
